We develop amplification-free, OR-gated CRISPR-Cascade assays for ultra-sensitive pathogen detection directly from whole blood, eliminating nucleic acid purification. Our dual-blocking autocatalytic strategy achieves attomolar sensitivity with low nonspecific signal.

• OR-gated multiplex detection: Simultaneous detection of multiple pathogens using a single CRISPR-Cascade reaction with OR-gate logic.
• Dual-blocking strategy: BNA and gRNA blocking to suppress nonspecific signal and enable attomolar sensitivity without amplification.
• Kinetic modeling: Mathematical modeling of CRISPR-Cascade kinetics to optimize assay design.

We develop a biphasic blood drying platform — a new biomaterial that enables simultaneous inhibitor inactivation and nucleic acid amplification directly from whole blood, without purification. Dried blood acts as a reusable biological scaffold for repeated diagnostics.

• DNA virus detection: Dried blood matrix for HBV, MRSA, E. coli — 10 IU mL⁻¹ LOD within 1.5 hours.
• RNA virus detection: Biphasic RNA amplification for Zika and HCV from whole blood.
• Materials characterization: Porosity, surface properties, inhibitor inactivation mechanisms of dried blood.

We build smartphone-integrated point-of-care platforms for simultaneous detection of SARS-CoV-2, Influenza, and RSV, including variant identification, using temperature-controlled fluorescence detection with contamination-free cartridges.

• Smartphone fluorimeter: Dual-port, pocket-size fluorimeter linked to a smartphone for rapid molecular assays at point-of-care.
• Variant identification: Microfluidic device for detection of early strains and B.1.1.7 variant of SARS-CoV-2.
• Respiratory panel: Simultaneous multiplex detection of SARS-CoV-2, Influenza A/B, and RSV.

We develop culture-free diagnostic platforms for sepsis that detect and gram-type bacteria directly from whole blood within 30 minutes, eliminating the 2–5 day blood culture bottleneck in current clinical practice.

• Gram-typing panel: Biphasic duplex-LAMP assay for gram-positive and gram-negative bacteria directly from whole blood.
• 30-minute CRISPR detection: OR-gated CRISPR-Cascade for sepsis pathogens without amplification.
• Clinical translation: Validation with patient samples toward point-of-care sepsis diagnosis.